NCT00015925View on ClinicalTrials.gov

MS-275 in Treating Patients With Hematologic Cancer

PHASE1CompletedINTERVENTIONAL
Timeline

Start Date

February 28, 2001

Conditions
LeukemiaMultiple Myeloma and Plasma Cell NeoplasmMyelodysplastic SyndromesMyelodysplastic/Myeloproliferative Diseases
Interventions
DRUG

entinostat

Trial Locations (2)

21201

Greenebaum Cancer Center at University of Maryland Medical Center, Baltimore

21231

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

OTHER

NCT00015925 - MS-275 in Treating Patients With Hematologic Cancer | Biotech Hunter | Biotech Hunter